ANIMAL LEGAL DEFENSE FUND, the American Society for the
Prevention of Cruelty to Animals, the Marin Humane Society,
Wisconsin Family Farm Defense Fund, John Kinsman, Michael
Cannell, Humane Farming Association, Association of
Veterinarians for Animal Rights, People for the Ethical
Treatment of Animals, Plaintiffs-Appellants,
v.
Donald J. QUIGG and C. William Verity, Defendants-Appellees.
No. 90-1364.
United States Court of Appeals,
Federal Circuit.
April 30, 1991.
Valerie Stanley, Galvin, Stanley & Hazard, Washington, D.C., argued for plaintiffs-appellants. Steven M. Wise, Fraser & Wise, P.C., Boston, Mass., argued for plaintiffs-appellants. Joyce S.A. Tischler, Animal Legal Defense Fund, San Rafael, Cal., was on the brief for plaintiffs-appellants. Kenneth D. Ross, Ross & Harrington, Chicago, Ill., of counsel.
John F. Daly, Dept. of Justice, Washington, D.C., argued for defendants-appellees. Stuart M. Gerson, Asst. Atty. Gen., William T. McGivern, U.S. Atty., Barbara L. Herwig, Dept. of Justice, Washington, D.C., were on the brief for defendants-appellees. Also on the brief was Fred E. McKelvey, Sol., U.S. Patent & Trademark Office, Arlington, Va., of counsel.
Before NIES, Chief Judge, and MARKEY, ARCHER, MAYER and LOURIE, Circuit Judges.1
NIES, Chief Judge.
This is an appeal from the order of the District Court for the Northern District of California (Smith, J.) granting defendants' motion to dismiss the complaint in Animal Legal Defense Fund v. Quigg,
* Section 101 of Title 35, United States Code, provides the statutory definition of the subject matter upon which a patent may be granted:
Sec. 101 Inventions patentable
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
35 U.S.C. Sec. 101 (1988). In 1980, the Supreme Court decided Diamond v. Chakrabarty,
A decision by the Board of Patent Appeals and Interferences in Ex parte Allen, [2 USPQ2d 1425] (Bd.App. & Int. April 3, 1987), held that claimed polyploid oysters are nonnaturally occurring manufactures or compositions of matter within the meaning of 35 U.S.C. 101. The Board relied upon the opinion of the Supreme Court in Diamond v. Chakrabarty,
The Board's decision does not affect the principle and practice that products found in nature will not be considered to be patentable subject matter under 35 U.S.C. 101 and/or 102. An article of manufacture or composition of matter occurring in nature will not be considered patentable unless given a new form, quality, properties or combination not present in the original article existing in nature in accordance with existing law. [Citations omitted].
A claim directed to or including within its scope a human being will not be considered to be patentable subject matter under 35 U.S.C. 101. The grant of a limited, but exclusive property right in a human being is prohibited by the Constitution. Accordingly, it is suggested that any claim directed to a non-plant multicellular organism which would include a human being within its scope include the limitation "non-human" to avoid this ground of rejection. The use of a negative limitation to define the metes and bounds of the claimed subject matter is a permissible form of expression. In re Wakefield,
Accordingly, the Patent and Trademark Office is now examining claims directed to multicellular living organisms, including animals. To the extent that the claimed subject matter is directed to a non-human "nonnaturally occurring manufacture or composition of matter--a product of human ingenuity" (Diamond v. Chakrabarty ), such claims will not be rejected under 35 U.S.C. 101 as being directed to nonstatutory subject matter. [Hereinafter "Notice" or "Rule".]2
1077 Official Gazette 24 (April 21, 1987).
More than a year after this Notice was published, the various plaintiffs3 filed suit in district court alleging in Count I that the Commissioner of Patents and Trademarks had violated the APA in issuing this Rule without complying with the public notice and comment period of the APA, 5 U.S.C. Sec. 553 (1988). Plaintiffs sought to enjoin the PTO from approving or issuing any patents on multicellular living organisms, including animals,4 or taking any action to effectuate the Rule, until it complied with the APA procedural requirements. In Count II plaintiffs alleged that the Commissioner violated section 706(2)(C) of the APA, 5 U.S.C. Sec. 706(2)(C) (1988), by acting in excess of statutory authority under the Patent Act, 35 U.S.C. Sec. 1, et seq. As relief under Count II, plaintiffs sought a declaration that the Commissioner acted in excess of his statutory jurisdiction or authority by including animals as patentable subject matter and an injunction against his issuance of any patents on multicellular living organisms, including animals, until authorized and mandated to do so by Congress. Defendants filed a motion to dismiss the complaint for failure to state a claim, and this motion was granted by the district court.
The district court expressly assumed without deciding that the various plaintiffs had standing and based the order of dismissal of Count I solely on its conclusion that the Rule fell outside the public notice and comment provisions of the APA, 5 U.S.C. Sec. 553(b), (c) (1988). Animal Legal Defense Fund,
The various plaintiffs then appealed that order of dismissal to the United States Court of Appeals for the Ninth Circuit. While recognizing that the APA created the causes of action, that court issued an order transferring the appeal to the Court of Appeals for the Federal Circuit. See Animal Legal Defense Fund v. Quigg,
Appellants not only seek to overturn the district court's rulings of no procedural error or abuse of authority but also urge us to hold that "animal" patents are not patentable subject matter under section 101. The government urges affirmance of the court's rulings and also urges affirmance of the judgment on the alternative ground raised below, namely, that appellants lack standing.6 The issue of standing on which we rule against appellants is, of course, dispositive of all other issues.
II
Standing
Under Article III Sec. 2 of the Constitution, the judicial power of courts created under Article III extends only to actual "cases" or "controversies". One aspect of a "case" or "controversy" is that "the litigant is entitled to have the court decide the merits of the dispute or of particular issues." Warth v. Seldin,
To establish standing to sue, as Article III Sec. 2 has been interpreted, a party must, "at an irreducible minimum," show (1) "that he personally has suffered some actual or threatened injury as a result of the putatively illegal conduct" (personal injury), (2) that "the injury 'fairly can be traced to the challenged action' " (causation), and (3) that the injury "is likely to be redressed by a favorable decision" (effective relief). Valley Forge Christian College v. Americans United for Separation of Church and State, Inc.,
As a preliminary matter, we note, as appellants point out, that this case comes before us as a result of the district court's having granted a motion to dismiss pursuant to Fed.R.Civ.P. 12(b)(6). "For purposes of ruling on a motion to dismiss for want of standing, both the trial and reviewing courts must accept as true all material allegations of the complaint, and must construe the complaint in favor of the complaining party." Warth v. Seldin,
III
Count I
A.
Count I of the complaint alleges that the putative illegal conduct lies in the Commissioner's failure to publish a notice of his proposed action in the Federal Register as required by 5 U.S.C. Sec. 553(b); his failure to allow interested persons an opportunity to submit data and arguments per section 553(c); and his failure to state the basis and purpose of the Notice following consideration of public comment.
Every organizational plaintiff in this case alleges that it was injured as a result of its having been denied participation in the PTO's rulemaking process. See, e.g., Trustees for Alaska v. Hodel,
Plaintiff, ANIMAL LEGAL DEFENSE FUND, (hereinafter "ALDF") is a national nonprofit corporation, organized and existing under California law, with its principal place of business in San Rafael, California. ALDF's purposes and activities include: the initiation of and participation in federal and state legal actions and administrative rulemaking proceedings, the provision of information and legal opinions to its members, the general public and governmental agencies, and the advocacy of the interests of its members in connection with: the furtherance of the care and welfare of animals, including farm, research and wild animals, and any rule, policy, act, omission, or neglect which causes or permits physical pain, behavioral distress, suffering, debilitation and/or death to animals. ALDF works to ensure that important governmental decisions affecting the lives and interests of animals are based on a rational analysis and made according to the law.
Since its inception in 1979, ALDF has participated in numerous administrative rulemaking proceedings. It has an interest in participating in any rulemaking proceeding regarding the patenting of animals, in providing information and documentation to Defendants, in providing its members and the public with information about any proposed rule to patent animals, and in advocating the interests of its members.
ALDF's purposes and activities have been and will continue to be frustrated and adversely affected by Defendants' new rule and its refusal to provide the public with notice and an opportunity to comment prior to the adoption of its new rule. ALDF has had to and will continue to have to devote significant financial resources to counteract the Defendants' unlawful actions. Plaintiff, ALDF, sues on behalf of itself and its members who are injured in their ability to carry out the purposes and activities of the organization due to Defendants' actions.
Those of PETA offer little variation:
Plaintiff, People for the Ethical Treatment of Animals (hereinafter "PETA") is a national nonprofit corporation with over 250,000 members and supporters. The purposes and activities of PETA include: to protect and enhance the status of animals, and to educate the general public about the issues of animal rights and systematized animal abuse, to participate in federal and state legislative and administrative rulemaking proceedings, to provide information to its members and the general public and to influence governmental decision-making on behalf of its members. PETA has an interest in providing information to Defendants which may have an impact on Defendants' formulation of any rule regarding the patenting of animals. PETA has an interest in ascertaining the underlying rationale for Defendants' new rule before it becomes finalized and providing its members and the public with such information, along with information about the consequences of such a rule, in order that PETA and its members may participate meaningfully in the decision making process. PETA's purposes, activities and interests have been and will continue to be frustrated and adversely affected by Defendants' refusal to provide the public with notice and the opportunity to comment prior to adopting the new rule. PETA will have to devote significant financial resources to counteract Defendants' unlawful actions.
Similar allegations are echoed by ASPCA, MHS, WFFDF, HFA and AVAR.
Whether there is any viability in such allegation of injury by reason of the alleged procedural defect,7 namely, the Commissioner's failure to provide public notice and comment procedures in adopting the rule, depends on the resolution of an issue of law: Was the Commissioner required to comply with section 553 before issuing the Rule? For reasons which follow, we conclude he was not. Thus, appellants' allegations of injury also fail as a matter of law.
B.
Under section 553 of the APA, certain agency action requires prior public notice and comment. As provided therein:
(b) General notice of proposed rule making shall be published in the Federal Register, unless persons subject thereto are named and either personally served or otherwise have actual notice thereof in accordance with law....
* * * * * *
(c) After notice required by this section, the agency shall give interested persons an opportunity to participate in the rule making through submission of written data, views, or arguments....
5 U.S.C. Sec. 553(b), (c). Notice and public comment, however, is not required for agency action if it falls within the terms of subsection (A) of section 553(b):
Except when notice or hearing is required by statute, this subsection does not apply--
(A) to interpretative rules, general statements of policy, or rules of agency organization, procedure, or practice....
Courts interpreting section 553 generally speak in terms of "substantive" or "legislative" rules requiring notice and comment in contrast to the exempt "interpretative" rules of section 553(b) which do not. See, e.g., Seldovia Native Ass'n, Inc. v. Lujan,
The genesis and effect of the Notice demonstrates that it represents no change in the law effected by the Commissioner and that, in reality, it is merely "interpretative" of prior decisional precedent. As acknowledged by appellants, in 1981 the Supreme Court decided, in Diamond v. Chakrabarty,
Four days after the Board's decision in Allen, the Commissioner issued the Notice in issue here. The language used by the Commissioner in the Notice largely tracks the above history and the language of Allen. In the first paragraph, the Commissioner summarizes the foregoing decisional law of Allen, Hibberd, and Chakrabarty and, based on the conclusions of the Supreme Court and the Board as to the scope of section 101, states that the PTO "now considers nonnaturally occurring non-human multicellular living organisms, including animals, to be patentable subject matter within the scope of 35 U.S.C. 101." 1077 Official Gazette 24 (emphasis added). In the next paragraph, the Commissioner reiterates, as the Board recognized in Allen, 2 USPQ2d at 1426-27, that the scope of the "Board's decision does not affect the principle that products found in nature will not be considered to be patentable subject matter...." Finally, in the last paragraph, the Commissioner quotes language from the Supreme Court decision in Chakrabarty that a claim to a "nonnaturally occurring manufacture or composition of matter--a product of human ingenuity" will not be subject to a section 101 rejection. Id. The Notice clearly corresponds with the interpretations of section 101 set out by the Board in Allen and Hibberd, in reliance on Chakrabarty, with the only caveat being the statement that section 101 does not extend to humans.9 Thus, the Notice falls within the class of agency action which is merely interpretative of previous valid administrative action, and, as a result, represents no "change" in the law by the Commissioner. See Northern Illinois Gas Co. v. United States,
Appellants argue, nonetheless, that the Notice is "substantive" because it reverses a longstanding PTO policy whereby non-naturally occurring microorganisms were considered to fit within the definition of patentable subject matter, but the PTO "had long considered animals not to be patentable subjects." This argument at best merely ignores the Board's intervening interpretation of section 101 made in its Allen and Hibberd decisions and at worst treats the Board as the alter ego or agent of the Commissioner which it is not. If this were the case, the Board's decision in Allen would effectively be a decision by the Commissioner, and the Commissioner could not properly consider the Notice as "interpretative" of that decision. In essence, the appellants seek to tie the Board's authority to adjudicate patentability issues to the statutory grant of rule making authority given to the Commissioner. However, the Board's authority to decide the section 101 issue rests on an independent grant in section 7(b), which requires the Board to decide patent validity issues when properly raised in Board proceedings, and is independent from the Commissioner's authority to establish regulations. Specifically, this section reads:
(b) The Board of Patent Appeals and Interferences shall, on written appeal of an applicant, review adverse decisions of examiners upon applications for patents and shall determine priority and patentability of invention in interferences declared under section 135(a) of this title.
35 U.S.C. Sec. 7(b).10 Subsuming this authority within that of the Commissioner would impermissibly make the Board unable to decide legal questions of first impression through adjudication whenever the Commissioner would be required to follow section 553 notice and comment requirements. Cf. National Labor Relations Bd. v. Bell Aerospace Co.,
Appellants further argue that the Notice is "substantive" because it cuts off agency discretion to deny applications for "animal" patents during prosecution. Appellants contend that under W.C. v. Bowen,
Appellants read Bowen too broadly. A limitation of discretion, by itself, does not make an agency action "substantive." One must also look for the adverse effect of that limitation on an individual's rights and obligations. In Bowen, the court found that the limitation on the Secretary's discretion, resulting from a program under which certain Administrative Law Judge decisions had to be reviewed, adversely affected some claimants' asserted rights to Social Security disability benefits. In the context of the case before us, the comparable question would be whether any limitation on an examiner's discretion to disallow applications on section 101 grounds adversely affects any individual's existing rights and obligations.
Here appellants assert no adverse effect on any individual's rights to benefits under the patent statute. Rather, they assert that the general public has an interest in the statutory limitations to patentability. Essentially, appellants assert a right, as members of the public particularly interested in animals, to sue for what they perceive to be an unwarranted interference with the discretionary judgment of an examiner. However, it must be noted that whether patents are allowable for animal life forms is not a matter of discretion but of law. See Graham v. John Deere Co.,
Moreover, we find nothing in the law which gives rise to a right in nonapplicants to object to the way in which patent applications of others are prosecuted. A third party has no right to intervene in the prosecution of a particular patent application to prevent issuance of an allegedly invalid patent. See, e.g., Chicago Rawhide Mfg. Co. v. Crane Packing Co.,
Nor does the Notice adversely "affect existing rights and obligations" of patent applicants. The requirement of an adverse affect on a party's rights or obligations stems from the APA itself. See, e.g., 5 U.S.C. Secs. 552(a), 702 ("adversely affected" party). The effect of the Notice, if mandatory, means that the examiner will refrain from issuing a section 101 rejection, but patent applicants are not "adversely affected" by an examiner's failure to enter a rejection. If there is no rejection, the patent simply issues, and the ultimate resolution of the invalidity of the claims is deferred until challenged in court. Deferring resolution of validity issues does not adversely affect the legal rights of the applicant.
Appellants also argue that when the source of the agency authority is a statutory grant of general rulemaking authority made by Congress, rules enacted pursuant to that grant have "legislative" or "substantive" effect, because they carry the force and effect of law, and therefore are "substantive" for purposes of section 553. Applying this principle to the Notice, appellants contend first that the Notice had to have been issued pursuant to the grant of authority to the Commissioner to "establish regulations" set forth in 35 U.S.C. Sec. 6.
Addressing the latter point, nothing in the Notice suggests that the Commissioner invoked his section 6 authority in issuing the Notice. Moreover, the authority granted in section 6 is directed to the "conduct of proceedings" before the Office. A substantive declaration with regard to the Commissioner's interpretation of the patent statutes, whether it be section 101, 102, 103, 112 or other section, does not fall within the usual interpretation of such statutory language. See, e.g., General Elec. Co., Inc. v. Gilbert,
Further, if the Notice were issued under section 6, that fact does not mean that the Notice is ipso facto "substantive." If appellants' argument were correct, every action taken by an agency pursuant to statutory authority would be subject to public notice and comment under section 553. Such a result would vitiate the statutory exceptions in section 553(b) itself, here the exception for "interpretative" rules. We cannot so interpret section 553. See Mountain States Telephone & Telegraph Co. v. Santa Ana,
Having reviewed all of appellants' arguments, we are persuaded that the Commissioner's Notice falls within the "interpretative" exception to the section 553 public notice and comment procedures. Appellants thus have no standing to assert Count I of the Complaint by reason of "procedural harm."
Appellants allege other injuries, which we discuss in connection with Count II and hold to be insufficient for standing under that Count. If we were to assume these alleged injuries also relate to Count I, it would be a meaningless exercise to undertake any standing analysis here as to the sufficiency of those allegations. Our conclusion that the Notice is "interpretative" necessarily moots any further question of standing as to this Count.
IV
Count II
Count II alleges that the Commissioner's rule declaring the patentability of animals exceeds the authority delegated to the Commissioner under the patent statute. Thus, the allegation is that the Notice was issued in contravention of section 706(2)(C) of the APA, which reads:
To the extent necessary to decision and when presented, the reviewing court shall decide all relevant questions of law, interpret constitutional and statutory provisions, and determine the meaning or applicability of the terms of an agency action. The reviewing court shall--
* * * * * *
(2) hold unlawful and set aside agency action, findings, and conclusions found to be--
* * * * * *
(C) in excess of statutory jurisdiction, authority, or limitations, or short of statutory right[.]
5 U.S.C. Sec. 706(2)(C). (Emphasis added.) As relief for this alleged violation, appellants seek a declaration that "animals" are not patentable subject matter under section 101 and an injunction against the issuance of any "animal" patents.
A.
Injury-in-Fact to Farmers and Farm Groups
As personal injury, various appellants, namely WFFDF, HFA,12 and the individual farmers, assert economic injury from the Commissioner's allegedly erroneous interpretation of section 101.13 The individual farmers, John Kinsman and Michael Cannell, allege in the complaint that:
Defendants' rule will increase Kinsman and Cannell's costs of operation, by forcing them to pay royalties to purchase patented, genetically altered animals, and, alternatively, will render Kinsman and Cannell less able to compete in the production of uniform and predictable traits and products, thereby lowering their annual net profits, all to their economic harm....
Similarly, WFFDF alleges on behalf of its members14 that economic injury will result from defendant's rule because:
Said rule will: increase such members' costs of operation by forcing them to purchase high priced "patented" animals, or lose profits producing genetically inferior "unpatented" animals; substantially increase livestock productivity and decrease herd size, causing a significant reduction in the number of small farms and negatively impacting their communities; substantially increase the economic competition that said members presently encounter, render these members unable or less able to compete in producing uniform and predictable traits or products; accelerate farm consolidation; and drive many of these members out of the farming business altogether.
As these appellants point out, the Commissioner concedes that the above allegations of economic injury, which must be assumed to be true, suffice to establish a judicially cognizable personal injury to them. See Association of Data Processing Serv. Orgs. Inc.,
The element of causation requires a party to show that "the injury must be fairly traceable to the challenged action." Allen v. Wright,
It is readily apparent that because the alleged injuries depend upon issuance of a patent, such injuries are speculatively dependent at a minimum on the acts of potential inventors who must develop novel transgenic non-naturally occurring animals, specifically farm animals; who must decide to file an application for patent on those animals rather than, for example, maintaining their discoveries as trade secrets; and who must ultimately successfully prosecute such applications to issuance as a patent. Appellants would, nevertheless, link such third party action to the government because inventors have been "encouraged" to seek patent protection by the Notice.
The Court's reasoning in the previously mentioned Simon case is applicable here. In Simon,
The complaint here alleged only that petitioners, by the adoption of Revenue Ruling 69-545, had "encouraged" hospitals to deny services to indigents. [Footnote omitted.] The implicit corollary of this allegation is that a grant of respondents' requested relief, resulting in a requirement that all hospitals serve indigents as a condition to favorable tax treatment, would "discourage" hospitals from denying their services to respondents. But it does not follow from the allegation and its corollary that the denial of access to hospital services in fact results from petitioners' new Ruling, or that a court-ordered return by petitioners to their previous policy would result in these respondents' receiving the hospital services they desire.
Id. at 42,
Given the action taken by the IRS, the Revenue Ruling granting hospitals favorable tax treatment, and the injury alleged, denial of hospital services to indigents, the Court concluded that "it [was] purely speculative whether the denials of service specified fairly can be traced to [the IRS]'s encouragement or instead result from decisions made by hospitals without regard to tax implications." Id. at 42-43,
The Court also appears to have based its decision at least in part on the lack of a likelihood that the indigents' injuries would be redressed by a favorable decision. Consideration of the effectiveness of a remedy may well further illuminate whether the alleged illegal action caused the injury. See Wright,
Thus, the Court directed that the complaint in Simon be dismissed for want of standing because "[s]peculative inferences [were] necessary to connect [indigents'] injury to the challenged actions of the [IRS]." Id. In the case at bar, we conclude that the injuries of the farmers cannot fairly be traced to the encouragement of third parties to engage in research and development. Like the third party action in Simon, the action of inventors and investors resulting from the Commissioner's "encouragement" is highly speculative. See also Wright,
As previously indicated, the farmers' alleged injuries are (1) having to pay increased costs in the form of royalties on patented animals and (2) suffering decreased profits because of competition from more productive non-naturally occurring animals. With respect to the alleged "royalties" injury, farmers cannot be forced to purchase improved animals and pay the premium (i.e., "royalty") which the farmers say is likely to be asked. Indeed, their allegation that their costs of operation will increase by reason of "royalties" is at best speculative. The motivation to purchase normally arises from the prospect of an economic advantage. Further, the ability of a market participant to affect price, i.e., exert market power, depends on whether competitive patented or non-patented animals are available. This in turn depends on the speculative activities of third party competitors whose market actions would determine the existence and extent of acceptable, noninfringing substitutes in the relevant product market. See Jefferson Parish Hospital Dist. No. 2 v. Hyde,
Similarly, the farmers' alleged injury from increased competition can only result from the development and commercialization of genetically improved animals--not from the grant of a patent. We do not denigrate the stimulation of invention that the possibility of patent protection provides. See Bonito Boats, Inc. v. ThunderCraft Boats, Inc.,
The grant or denial of patents on micro-organisms is not likely to put an end to genetic research or to its attendant risks. The large amount of research that has already occurred when no researcher had sure knowledge that patent protection would be available suggests that legislative or judicial fiat as to patentability will not deter the scientific mind from probing into the unknown any more than Canute could command the tides. Whether respondent's claims are patentable may determine whether research efforts are accelerated by the hope of reward or slowed by want of incentives, but that is all.
This perceptive comment is of no less force just because we are faced now with genetically altered animals. It is equally apt. Research and commercialization of genetically improved animals may be stimulated by the Commissioner's interpretation, even if wrong. But appellants do not assert, indeed cannot assert, a legal right to be free from the competition attendant the development of improved animals.
We are unpersuaded to reaching a contrary result under the authorities cited by appellants where the Supreme Court found standing to exist. In Blum v. Yaretsky,
Appellants also erroneously believe that SCRAP supports their position on standing. In SCRAP "although the injury was indirect and there was [an] attenuated line of causation,
B.
Injury-in-Fact to Animal Protection Associations
The standing allegations of the animal protection associations are patently insufficient under controlling precedent. As the various appellants correctly point out, the alleged injury need not be economic in nature to constitute "injury" for purposes of standing.
[T]he interests alleged to have been injured "may reflect 'aesthetic, conservational, and recreational' as well as economic values." But broadening the categories of injury that may be alleged in support of standing is a different matter from abandoning the requirement that the party seeking review must himself have suffered an injury.
Sierra Club,
If any group with a bona fide "special interest" could initiate such litigation, it is difficult to perceive why any individual citizen with the same bona fide special interest would not also be entitled to do so.
Thus, HFA and AVAR have failed to allege any legally cognizable injury.
ASPCA and MHS attempt to escape from the mere "value preference" category by reason of state statutes that delegate to these organizations certain police power to protect and care for animals. They allege they will need to increase their budgets and enforcement staffs by reason of the increased experimentation on animals fostered by the potential for patent protection. The government counters this point first by uncontroverted assertions that the state statutes impose no duties on the organizations so that any action they might take would be purely voluntary, and thus, no different from the action of anyone interested in protecting animals. Nevertheless, we recognize that courts have found the type of allegations made by ASPCA and MHS here sufficient for showing personal injury. See, e.g., International Primate Protection League,
Turning to causation, however, we conclude that the injury alleged by these groups cannot be attributed to the Commissioner's interpretation of section 101 under the reasoning of the Supreme Court's decision in Simon previously discussed. With respect to these associations, not only does the need for action by independent third parties, who must successfully invent and prosecute to issuance patent applications for "animals," sever any link between the injury and governmental action, see supra at 933-934, but also additional acts by third parties are required. The potential for patent protection leading to increased experimentation must lead to increased cruelty. Yet for increased experimentation to lead to increased cruelty, appellants would have to allege that the existing animal cruelty laws are insufficient or that the issuance of "animal" patents would "encourage" researchers to disobey these laws. See, e.g., Animal Welfare Act of December 23, 1985, Pub.L. No. 99-198, 99 Stat. 1645 (1985), 9 C.F.R. Secs. 1.1-12.10 (1990) (Regulations concerning animal welfare and implementing the Animal Welfare Act, specifically 9 C.F.R. Secs. 3.1-3.142 with respect to standards for humane handling, care and treatment); N.Y.Pub.Health Law Sec. 504 (1990); Cal.Penal Code Sec. 597 (1991); see also International Primate Protection League v. Institute for Behavioral Research, Inc.,
V
Zone of Interests
The Supreme Court has enunciated one further limitation on standing known as the "zone of interests" test. A party bringing suit must come "within the zone of interests addressed by the substantive provisions of the law they seek to invoke." Air Courier Conference, --- U.S. ----,
Appellants invoke section 702 of the APA which gives standing to any person "adversely affected or aggrieved by an agency action within the meaning of a relevant statute." 5 U.S.C. Sec. 702. Consequently, to fall within the "zone of interests" protected by section 702, it is necessary to be within the "zone of interests" addressed by a "relevant statute." Pointing to both the APA and the patent laws generally, appellants argue that they fall within the zone of interests protected by either statute. We reject appellants' position. The patent statute, not section 706(2)(C) nor 553 of the APA, is the "relevant statute" under section 702, and appellants have not alleged facts which place them within the "zone of interests" addressed by the patent laws.
Appellants would have us consider the APA itself as a "relevant statute" under section 702. The Supreme Court has given recent guidance on the meaning of "relevant statute" in section 702 of the APA. In Lujan v. National Wildlife Federation, --- U.S. ----,
[t]he relevant statute is, of course, the statute whose violation is the gravamen of the complaint--both the FLPMA and NEPA.
See also Air Courier Conference, --- U.S. at ----,
We believe the above analysis applies equally to eliminate appellants' reliance on section 553 of the APA as a basis for establishing they are within a zone of interest. Moreover, in rejecting an argument that plaintiffs were injured by not having the benefit of section 553 notice and comment, the Court of Appeals for the District of Columbia Circuit in Capital Legal Foundation v. Commodity Credit Corp.,
Were we to accept [Capital's] imaginative argument, every asserted violation by an agency of its own regulations could be recharacterized as "de facto rulemaking" outside the APA, and therefore arguably open to challenge as procedurally-flawed by any person who claims he, she, or it would have participated had the rulemaking occurred inside the APA. We are certain that Congress, in adopting the APA, had no such universal standing design in mind. [Footnote omitted.]
See also Simon,
Here, if appellants are to be deemed within the "zone of interests" for standing purposes under section 702 of the APA, they must fall within the "zone of interests" addressed by the patent laws. Appellants baldly claim that they fall within the "zone of interests" addressed by the patent laws because patents "are issued not for private benefit but for the public good" and that "[p]atent case law emphasizes the importance of the public interest and the constitutional requirement of a public benefit." Under appellant's theory, it would follow that since appellants represent "members of the public who will suffer injury due to the new [and wrongful] PTO rule," they are "arguably within the zone of interests" protected by the Patent Act. In essence appellants' claim the patent statute's "zone of interests" encompasses any member of the public who perceives they will be harmed by an issued patent which they believe to be invalid. We cannot agree that the "zone of interests" of the patent laws is so broad. Under such an interpretation, we would, for example, be opening the door to collateral attack on the validity of issued patents; any competitor could simply file suit against the Commissioner challenging a patent's validity. This we decline to do. The structure of the Patent Act indicates that Congress intended only the remedies provided therein to ensure that the statutory objectives would be realized. See, e.g., 35 U.S.C. Secs. 281-282 (in civil action for infringement, validity of patent can be challenged defenses); 145 (civil action to obtain patent); 146 (civil action in case of interference); 135 (interference action; subsection (c) provides that discretionary actions by the Commissioner under that subsection are reviewable under section 10 of the APA); 291 (civil action in case of interfering patents); 301-02 (reexamination proceedings).
We see much similarity between the situation here and that in Block v. Community Nutrition Inst.,
VI
Accepting the allegations of the complaint as true and drawing all inferences favorable to appellants, we conclude that appellants have failed to allege facts sufficient to meet the standing requirements of Article III Sec. 2 of the Constitution.
AFFIRMED ON OTHER GROUNDS.
Notes
This case was originally heard by a five-judge panel as authorized under 28 U.S.C. Sec. 46(c) (1988)
We attach no legal significance to a difference in these terms and use them interchangeably herein. There is no contention that the Notice does not fall within the APA definition of "rule" in 5 U.S.C. Sec. 551(4) (1988)
The various plaintiffs in this case are nine:
Animal Legal Defense Fund (ALDF), The American Society for the Prevention of Cruelty to Animals (ASPCA), The Marin Humane Society (MHS), Wisconsin Family Farm Defense Fund (WFFDF), John Kinsman, Michael Cannell, Humane Farming Association (HFA), Association of Veterinarians for Animal Rights (AVAR), and People for the Ethical Treatment of Animals (PETA).
The Rule covers only non-naturally occurring animals; plaintiffs erroneously speak of the Rule as covering all "animals."
The parties do not dispute here the legality of the Ninth Circuit's transfer and do not question whether a suit seeking compliance with the APA notice and comment provisions in administering the patent laws is a suit "arising under" the patent laws in accordance with 28 U.S.C. Sec. 1338(a) (a necessary prerequisite for Federal Circuit jurisdiction under Sec. 1295(a)(1)). See U.S. Philips Corp. v. Windmere Corp.,
Granfinanciera v. Nordberg,
In light of our disposition of the legal question whether the Notice is "substantive" or "interpretative" under section 553, we do not address appellees' argument that actual injury cannot rest solely on allegations of denial of input into the rulemaking process. See, e.g., Capital Legal Foundation v. Commodity Credit Corp.,
It is interesting to note that the first patent on a non-naturally occurring animal issued within a month after this court affirmed the Allen decision. See U.S. Patent No. 4,736,866 (issued April 12, 1988) (The "Harvard mouse")
None of the plaintiffs here argue that the inclusion of the express limitation on the interpretation of section 101 as not applicable to humans serves to make the Rule "substantive" rather than "interpretative," nor could they based on their allegations. Indeed, all the appellants' allegations of injury, procedural, economic and organizational, focus on the treatment of animals or the adverse economic effects resulting from the issuance of patents on animals. Thus, the question whether section 553 requirements extend to that part of the Rule which precludes the patentability of humans is not in issue and we do not address it
While the Commissioner may sit on the Board, in that capacity he serves as any other member. See 35 U.S.C. Sec. 7(a)
Allowance will to some extent reduce the opportunities for the Board to revisit the question of section 101 subject matter but that does not effect a change in procedures or substantively affect any rights. In fact, the reduction of the Board's opportunities for revisiting Allen is limited to applications where the examiner makes no final rejection. In cases where a rejection on another basis is made and the applicant appeals, the Board may revisit Allen by deciding to enter a new rejection based on section 101. See 37 C.F.R. Sec. 1.196 (1990)
Since this appeal is from a motion to dismiss, we must, as previously stated, draw all inferences favorable to appellants. Thus, we interpret HFA to assert an economic injury to its member farmers similar to that alleged by WFFDF
The District Court viewed the Count II issue, once determining that the rule was "interpretative" under section 553(b)(A), as having been reduced to whether the Commissioner had authority to issue a non-binding Notice reflective of Board decisional precedent. Were that the proper inquiry, we would agree with the district court that because the Notice is interpretative under section 553(b)(A) of the APA:
[T]he PTO is authorized to issue such rules or "notices," 5 U.S.C. section 553, and because the Rule neither abridges nor enlarges the rights of anyone the PTO could not, as a matter of law, have exceeded its statutory authority in promulgating it.
Animal Legal Defense Fund,
Nevertheless, as on motion to dismiss for want of standing we must draw all reasonable inferences in favor of appellants based on the allegations in the complaint, we assume that, as Count II of the complaint alleges, the Notice represents the Commissioner's independent interpretation of section 101.
We take as true for purposes of reviewing a motion to dismiss, that WFFDF's organizational purposes and activities, as somehow documented by its by-laws or the like, encompass the protection of farmer members from economic injury. Thus, WFFDF stands in the shoes of its members. See Hunt v. Washington State Apple Advertising Comm'n,
A patent provides only a right to exclude others from practicing the invention for a limited time. See 35 U.S.C. Sec. 154; Eli Lilly and Co. v. Medtronic, Inc., --- U.S. ----,
